Full history for every metric is available with a Kvantra account
ERYTECH Pharma S.A. (ERYP)
Key financial summary
Financials in EUR| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 3 | 4 | 3 | 0 | 0 | 0 | 0 |
| Operating profit | €m | -3 | -3 | |||||
| Net profit | €m | -34 | -38 | -63 | -73 | -54 | -0 | -0 |
| EPS reported | € | -0.01 | -0.01 | |||||
| Operating cashflow per share | € | -1.02 | -1.02 | |||||
| Capex per share | € | 0.00 | 0.00 | |||||
| FCF per share | € | -1.03 | -1.03 | |||||
| Free cash flow | €m | -32 | -0 | |||||
| Net debt | €m | -25 | -29 | |||||
| Book value equity | €m | 23 | 23 | |||||
| Book value per share | € | 0.76 | 0.76 | |||||
| Number of shares | m | 31.02 | 31.02 | |||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.41 | 1.79 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.30 | -96.36 | |||||
| EV/EBITDA LTM | x | -3.43 | 1.71 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -2.38% | -1.06% | |||||
| FCF Yield | % | -333.09% | -1.04% | |||||
| Quality | ||||||||
| ROE | % | -0.97% | -0.98% | |||||
| ROIC | % | 5.81% | 5.81% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.35 | -0.03 | |||||
| Net Debt/EBITDA | x | -5.53 | -5.53 | |||||
| EBIT/Net interest | x | -2.05 | -2.05 | |||||
| Net debt/market cap | % | -264.23% | -68.23% | |||||
| Net debt/Equity | x | -1.08 | -1.22 | |||||
| Gross debt/equity | x | 0.58 | 0.58 | |||||
Company overview
ERYTECH Pharma S.A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases. Its operations are based in France and the United States. The company's most advanced investigational therapy, eryaspase, is currently undergoing Phase 3 clinical trials for second-line pancreatic cancer, and Phase 2 studies for patients with triple-negative breast cancer and second-line acute lymphoblastic leukemia. Furthermore, ERYTECH is developing erymethionase, a preclinical candidate that employs methionine-γ-lyase encapsulated in red blood cells to target methionine-dependent tumors. Founded in 2004, the firm's headquarters are located in Lyon, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ERYTECH Pharma S.A. (ERYP)
ERYTECH Pharma S.A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases. Its operations are based in France and the United States. The company's most advanced investigational therapy, eryaspase, is currently undergoing Phase 3 clinical trials for second-line pancreatic cancer, and Phase 2 studies for patients with triple-negative breast cancer and second-line acute lymphoblastic leukemia. Furthermore, ERYTECH is developing erymethionase, a preclinical candidate that employs methionine-γ-lyase encapsulated in red blood cells to target methionine-dependent tumors. Founded in 2004, the firm's headquarters are located in Lyon, France.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free